{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T09:26:34Z","timestamp":1750843594229},"reference-count":6,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T00:00:00Z","timestamp":1699401600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,20]]},"DOI":"10.1093\/bjd\/ljad342","type":"journal-article","created":{"date-parts":[[2023,11,10]],"date-time":"2023-11-10T14:37:31Z","timestamp":1699627051000},"page":"138-138","source":"Crossref","is-referenced-by-count":1,"title":["Targeting interleukin (IL)-4\/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in\u00a0melanoma and immunotherapy: reply from\u00a0the authors"],"prefix":"10.1093","volume":"190","author":[{"given":"William D","family":"Shipman","sequence":"first","affiliation":[{"name":"Departments of Dermatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katelyn","family":"Singh","sequence":"additional","affiliation":[{"name":"Departments of Dermatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffery M","family":"Cohen","sequence":"additional","affiliation":[{"name":"Departments of Dermatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan","family":"Leventhal","sequence":"additional","affiliation":[{"name":"Departments of Dermatology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Damsky","sequence":"additional","affiliation":[{"name":"Departments of Dermatology"},{"name":"Pathology, Yale University School of Medicine , New Haven, CT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mary M","family":"Tomayko","sequence":"additional","affiliation":[{"name":"Departments of Dermatology"},{"name":"Pathology, Yale University School of Medicine , New Haven, CT , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,11,8]]},"reference":[{"key":"2023122107153303700_ljad342-B1","doi-asserted-by":"crossref","DOI":"10.1093\/bjd\/ljad324","article-title":"Targeting interleukin (IL)-4\/IL-13 in immune checkpoint inhibitor-induced bullous pemphigoid: a cautionary note on the beneficial effect of T helper 2 immunity in melanoma and immunotherapy","volume":"190","author":"Guerrero-Juarez","year":"2023","journal-title":"Br J Dermatol"},{"key":"2023122107153303700_ljad342-B2","doi-asserted-by":"crossref","first-page":"339\u201341.","DOI":"10.1093\/bjd\/ljad149","article-title":"Immune checkpoint inhibitor-induced bullous pemphigoid is characterized by interleukin (IL)-4 and IL-13 expression and responds to dupilumab treatment","volume":"189","author":"Shipman","year":"2023","journal-title":"Br J Dermatol"},{"key":"2023122107153303700_ljad342-B3","doi-asserted-by":"crossref","first-page":"953\u201360","DOI":"10.1001\/jamadermatol.2023.2428","article-title":"Evaluation of dupilumab in patients with bullous pemphigoid","volume":"159","author":"Zhao","year":"2023","journal-title":"JAMA Dermatol"},{"key":"2023122107153303700_ljad342-B4","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1016\/j.jaip.2022.05.019","article-title":"Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis","volume":"10","author":"Wechsler","year":"2022","journal-title":"J Allergy Clin Immunol Pract"},{"key":"2023122107153303700_ljad342-B5","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.cyto.2015.05.026","article-title":"Targeting of IL-4 and IL-13 receptors for cancer therapy","volume":"75","author":"Suzuki","year":"2015","journal-title":"Cytokine"},{"key":"2023122107153303700_ljad342-B6","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41586-020-2134-y","article-title":"A conserved dendritic-cell regulatory program limits antitumour immunity","volume":"580","author":"Maier","year":"2020","journal-title":"Nature"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad342\/53064889\/ljad342.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/1\/138\/54716041\/ljad342.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/1\/138\/54716041\/ljad342.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T13:32:13Z","timestamp":1703338333000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/190\/1\/138\/7386081"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,8]]},"references-count":6,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,11,8]]},"published-print":{"date-parts":[[2023,12,20]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad342","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,11,8]]}}}